Walter Straus Selected Research

2019-nCoV Vaccine mRNA-1273

3/2024	Global Safety Assessment of Adverse Events of Special Interest Following 2 Years of Use and 772 Million Administered Doses of mRNA-1273.
1/2023	Analysis of Myocarditis Among 252 Million mRNA-1273 Recipients Worldwide.
1/2022	A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Walter Straus Research Topics

Disease

2	Myocarditis (Carditis) 03/2024 - 01/2023
2	COVID-19 01/2023 - 01/2022
1	Anaphylaxis (Anaphylactic Shock) 03/2024
1	Pericarditis 03/2024
1	Mycoses (Diseases, Fungus) 08/2022
1	Chickenpox 08/2019
1	Neural Tube Defects (Exencephaly) 01/2019
1	Hepatitis B 09/2009
1	Infections 09/2009

Drug/Important Bio-Agent (IBA)

3	2019-nCoV Vaccine mRNA-1273IBA 03/2024 - 01/2022
3	VaccinesIBA 01/2022 - 09/2009
1	COVID-19 VaccinesIBA 03/2024
1	Messenger RNA (mRNA)IBA 01/2023
1	posaconazole FDA Link 08/2022
1	TriazolesIBA 08/2022
1	mRNA VaccinesIBA 01/2022
1	Chickenpox Vaccine (Vaccine, Varicella)IBA 08/2019
1	Raltegravir Potassium FDA Link 01/2019
1	Immunoglobulins (Immunoglobulin)IBA 09/2009
1	DNA (Deoxyribonucleic Acid)IBA 09/2009
1	Hepatitis B e AntigensIBA 09/2009
1	hepatitis B hyperimmune globulinIBA 09/2009
1	Thimerosal (Thiomersal)IBA 09/2009
1	Hepatitis B Vaccines (Hepatitis B Vaccine)IBA 09/2009

Therapy/Procedure

1	Salvage Therapy 08/2022